Evidence map›Paper›PMID 41142476›Full record

ArticleTherapeutic advances in medical oncology2025

SMARCA4-deficient dedifferentiated ovarian carcinoma with rapid progression during adjuvant platinum-based chemotherapy: a case report and implications for molecular-driven treatment strategies.

Markéta Bednarˇíková, Jitka Hausnerová, Petra Pokorná, Michal Felsinger, Svatopluk Richter, Lucie Ehrlichová, Jana Orlícˇková, Luboš Minář, Ondrˇej Slabý, Vít Weinberger

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Markéta BednarˇíkováDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID https://orcid.org/0000-0003-3189-7028
Jitka HausnerováDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Petra PokornáDepartment of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Michal FelsingerDepartment of Obstetrics and Gynecology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Svatopluk RichterDepartment of Radiology and Nuclear Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Lucie EhrlichováDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Jana OrlícˇkováCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Luboš MinářDepartment of Obstetrics and Gynecology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ondrˇej SlabýDepartment of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Vít WeinbergerDepartment of Obstetrics and Gynecology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavská 20, Brno 625 00, Czech Republic.ORCID https://orcid.org/0000-0003-4858-1951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dedifferentiated ovarian carcinomas (DDOC) are rare and aggressive malignancies characterized by a mixture of differentiated and undifferentiated tumor components, often associated with poor prognosis. This case report describes a 55-year-old woman initially diagnosed with early-stage high-grade endometrioid ovarian carcinoma who experienced rapid disease progression during adjuvant platinum-based chemotherapy, culminating in death within 4 months. Retrospective molecular analyses revealed pathogenic variants in the

Indexed as

case reportdedifferentiated ovarian carcinomapersonalized treatmentSLFN11SMARCA4SWI/SNF chromatin remodeling complex

Identifiers

PMID41142476
PMCPMC12547099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.